FLAVIN JOHN L 4
Research Summary
AI-generated summary
Pyxis Oncology (PYXS) Director John L. Flavin Receives 45,867‑Share Option
What Happened
- Director John L. Flavin received a grant (derivative award) on 2026-03-24 for 45,867 shares. The Form 4 reports the acquisition price as $0.00 (award/option), indicating this is a compensation grant rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-03-24; filing date: 2026-03-25 (timely).
- Transaction type/code: A = Award/Grant of a derivative security (option).
- Shares subject: 45,867 option shares; reported price: $0.00.
- Vesting: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to continued service (per footnote F1).
- Shares owned after transaction: Not disclosed in this filing.
- No indication of a 10b5‑1 plan, cashless exercise, sale, or tax‑withholding reported here.
Context
- This was an option award (derivative grant), not an exercise or sale—no immediate proceeds or share sales occurred. Such grants are commonly part of executive/director compensation and reflect long‑term incentive alignment, but do not by themselves indicate buying or selling sentiment. The award vests in one year if the director remains in service.